SBIR / STTR #MDA27BZ02-DV010

MDA seeks transfer-learning prototype for missile defense applications

MDA is seeking a Direct-to-Phase-II SBIR prototype to apply multi-fidelity transfer learning to Missile Defense System applications. - Government buyer: Department of War, Missile Defense Agency (MDA), through the Small Business Innovation Research Program. - Opportunity: Topic MDA27BZ02-DV010, “Multi-Fidelity Transfer Learning for Defense Applications.” The effort is research and development; no commercial OEMs, vendors, part numbers, or product quantities are specified. - Requested capability: Develop and demonstrate a prototype that uses low-fidelity training and transfer-learning methods with high-fidelity MDS simulations, including across classification levels. Demonstrate resource savings compared with traditional training and provide a human-machine interface and workflows integrated with existing MDS agent-training systems. - Conduct a representative case study using the prototype with representative data and models. - A later Phase III effort may mature and scale the capability for field use and integrate it into a system-level testbed. - Notable requirements: Proposals must demonstrate that Phase I technical merit and feasibility have been established and describe potential commercial applications. CMMC Level 2 (Self) is specified, and the technology is subject to export-control restrictions. Classified proposals are not accepted under the MDA SBIR program. - Performance period: MDA instructions anticipate a 24-month Phase II period; specific start and end dates are not provided.

Description

The Missile Defense Agency (MDA) topic is part of the 2027 Department of War SBIR BAA, Release 2, and is designated Direct to Phase II. Proposals should address the topic identified as “Multi-Fidelity Transfer Learning for Defense Applications”; the topic PDF is listed as an attachment, but its content is not provided in the source. Proposals must be submitted through the Defense SBIR/STTR Innovation Portal (DSIP), and MDA Direct to Phase II submissions must include documentation substantiating that the scientific and technical merit and feasibility described in the Phase I section have been met, along with potential commercial applications. The response deadline is January 6, 2027, and the source states a CMMC Level 2 (Self) requirement.

View original listing